Risk factors for hepatic veno-occlusive disease: A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen

Bone Marrow Transplantation

Volumn 42, Issue 7, 2008, Pages 449-454

  Cacchione, A ^a   LeMaitre, A ^a   Couanet, D Valteau ^a   Benhamou, E ^a   Amoroso, L ^a   Simonnard, N ^a   Hartmann, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CARBOPLATIN; CLONAZEPAM; ETOPOSIDE; HEPARIN; THIOTEPA; URSODEOXYCHOLIC ACID;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CHILD; CHILD CARE; CLINICAL FEATURE; CONTROLLED STUDY; CONVULSION; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; FEVER; FRANCE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; UNIVARIATE ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BUSULFAN; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CLONAZEPAM; ETOPOSIDE; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA; SEIZURES; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 54349112609     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.186     Document Type: Article

References (34)

1. Sucak GT, Aki ZS, Yagci M, Yegin ZA, Ozkurt ZN, Haznedar R. Treatment of sinusoidal obstruction syndrome with defibrotide: A single-center experience. Transplant Proc 2007; 39: 1558-1563.
2. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002; 22: 27-42.
3. Brugieres L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: Incidence, clinical course and outcome. Bone Marrow Transplant 1988; 3: 53-58.
4. Reiss U, Cowan M, MCMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
5. Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS. Incidence, survival and risk factors for the development of veno-occlusive disease in paediatric haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003; 32: 79-87.
6. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
7. Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with highdose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789-795.
8. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L et al. Risk factors for hepatic venoocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992; 10: 135-141.
9. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
10. Valteau-Couanet D, Fillipini B, Benhamou E, Grill J, Kalifa C, Couanet D et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: High toxicity and lack of efficacy. Bone Marrow Transplant 2005; 36: 939-945.
11. Garaventa A, Porta F, Rondelli R, Dini G, Meloni G, Bonetti F et al. Early deaths in children after BMT. Bone Marrow Transplant 1992; 10: 419-423.
12. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatrics patients: Evidence for dose dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736-741.
13. Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier-Lacombe MJ et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: A phase II study. Bone Marrow Transplant 1992; 9: 227-233.
14. Dupuis-Girod S, Hartmann O, Benhamou E, Doz F, Mechinaud F, Bouffet E et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996; 27: 87-98.
15. Ridola V, Grill J, Doz F, Gentet JC, Frappaz D, Raquin MA et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007; 110 156-163.
16. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, LaPierre V, Couanet D et al. Consolidation with busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937-942.
17. Mc Donald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
18. Styler MJ, Crilley P, Biggs J, Moul J, Copelan E, Topolsky D et al. Hepatic dysfunction following busulfan and cyclophoshamide myeloablation: A retrospective, multicenter analysis. Bone Marrow Transplant 1996; 18: 171-176.
19. Girinsky T, Benhamou E, Bourhis JH, Dhermain F, Guillot-Valls D, Ganansia V et al. A prospective randomized comparison of single dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 2000; 18: 981-986.
20. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281-291.
21. Horn B, Reiss U, Matthay K, McMillan A, Cowan M. Venoocclusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: A high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002; 29 409-415.
22. LaPierre V, Mahe C, Auperin A, Stambouli F, Oubouzar N, Tramalloni D et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005; 80: 314-319.
23. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Hematologica 2005; 90: 1396-1404.
24. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D et al. Defibrotide in the treatment of the children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189-195.
25. Richardson P, Bearman SI. Prevention and treatment of hepatic veno-occlusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998; 31: 267.
26. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067-1671.
27. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975-981.
28. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
29. Bouligand J, Boland I, Valteau Couanet D, Deroussent A, Kalifa C, Hartmann O et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979-986.
30. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862.
31. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013-1018.
32. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121-1124.
33. Bouligand J, Maitre AL, Valteau-Couanet D, Grill J, Drouard-Troalen L, Paci A et al. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clin Pharmacol Ther 2007; 82: 402-409.
34. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.